SCHEMBL6281765

SCHEMBL6281765

C/C(=N/NC(=N)N)c1cn(S(C)(=O)=O)c2ccc(Cl)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 5/20 0.36
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PLK4 O00444 1/20 0.34
CHEK1 O14757 1/20 0.34
AURKA O14965 1/20 0.34
CHUK O15111 1/20 0.34
DAPK3 O43293 1/20 0.34
JAK2 O60674 1/20 0.34
ROCK2 O75116 1/20 0.34
PAK4 O96013 1/20 0.34
CHEK2 O96017 1/20 0.34
CDK1 P06493 1/20 0.34
PIM1 P11309 1/20 0.34
PRKACA P17612 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281767 1.00 KDM1A (0.36) KDM1ALMNACYP1A2CYP2C9CYP2C19
SCHEMBL6285062 0.86 LMNA (0.46) KDM1ALMNACYP2C9CYP2C19MEN1
SCHEMBL6285056 0.86 LMNA (0.46) KDM1ALMNACYP2C9CYP2C19MEN1
SCHEMBL6282759 0.85 HTR6 (0.35) KDM1ALMNACYP1A2CYP2C9CYP2C19
SCHEMBL6282762 0.85 HTR6 (0.35) KDM1ALMNACYP1A2CYP2C9CYP2C19
SCHEMBL6287704 0.84 HTR3A (0.38) HTR3AALDH1A1ACLY
SCHEMBL6287700 0.84 HTR3A (0.38) HTR3AALDH1A1ACLY
SCHEMBL6284744 0.84 HTR3A (0.43) LMNAMEN1KMT2ASMN1; SMN2PLK4
SCHEMBL6284740 0.84 HTR3A (0.43) LMNAMEN1KMT2ASMN1; SMN2PLK4
SCHEMBL6286319 0.83 PSEN1 (0.34) KCNH2HTR3AALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A KDM1A 3696/4885LMNA 4212/4885CYP1A2 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.